Updated:
Hainan Haiyao
Hainan Haiyao was established in 1965 and restructured into a joint-stock company in 1992, eventually listing on the Shenzhen Stock Exchange.
Hainan Haiyao
Hainan Haiyao was established in 1965 and restructured into a joint-stock company in 1992, eventually listing on the Shenzhen Stock Exchange. Founder Liu Xicheng, a fixture on the Hurun Rich List, steered the company from a regional manufacturer into a national pharmaceutical player. The largest shareholder is Hainan Huatong Industrial Co., Ltd., holding roughly 23% of shares, with Shenzhen Nanfang Tongzheng Investment Co., Ltd. holding approximately 10%, linking the corporate structure to a broader network of Chinese industrial investors including ties to Chongqing Wanli New Energy. Hainan Haiyao's primary business spans research, development, manufacturing, and sale of pharmaceutical products, encompassing antibiotics, gastrointestinal drugs, and oncology treatments. Its investment posture is operationally anchored: the firm uses its balance sheet to secure exclusive distribution agreements and strategic partnerships rather than managing a discrete fund portfolio. For example, Hainan Haiyao holds a strategic distribution partnership with New Zealand-based AFT Pharmaceuticals for products such as Crystaderm in the Chinese market. The geographic focus centers on domestic Chinese healthcare delivery, with manufacturing concentrated at the Haikou Pharmaceutical Manufacturing Plant in Hainan province. As a Shenzhen-listed entity, the firm's scale and deployment capacity are tied to its public market capitalization and the personal wealth of its founder rather than a separately managed pool of investment assets. Liu Xicheng's presence on the Hurun Rich List signals significant but undisclosed family-office style capacity alongside the corporate entity. The company operates its headquarters at 192 Nanhai Avenue in Haikou, with industrial assets including its primary manufacturing plant and a portfolio of pharmaceutical patents and drug certificates across China. Hainan Haiyao's structural differentiator lies in its hybrid identity as a publicly traded operating company that effectively functions as a corporate venture arm for its founder. Unlike a pure family office or a standalone corporate VC, investment decisions are inseparable from the company's commercial pipeline, with deal flow driven by distribution rights, manufacturing scale, and regulatory approvals rather than traditional fund mandates.
General information
Firm type
Corporate Investor
Year founded
1965
AUM
Undisclosed
Location
Region
Asia
Country
China
City
Haikou
Corporate office
No. 192 Nanhai Avenue, Xiuying District, Haikou, Hainan 570311, China
Principals
Liu Xicheng
Founder
Sector focus
Frequently asked questions
Who controls investment decisions at Hainan Haiyao?
Investment decisions are driven by the listed company's board and senior management, with founder Liu Xicheng historically serving as Chairman and retaining significant influence. As a corporate investor, capital allocation ties directly to the pharmaceutical pipeline and commercial strategy rather than a separate investment committee structure. The firm's largest shareholder, Hainan Huatong Industrial Co., Ltd. with a roughly 23% stake, also holds sway over major strategic moves.
How does Hainan Haiyao source investment opportunities?
Opportunities arise primarily through the company's pharmaceutical operations and distribution network. Strategic partnerships, such as the agreement with AFT Pharmaceuticals for Chinese market distribution, are sourced through commercial relationships rather than blind fund commitments. The firm's manufacturing plant in Haikou and portfolio of drug certificates provide a platform for licensing and co-commercialization deals.
Is Hainan Haiyao a family office or a corporate investor?
Hainan Haiyao is a publicly traded corporate investor listed on the Shenzhen Stock Exchange, not a single family office. However, founder Liu Xicheng's personal wealth, recognized by the Hurun Rich List, introduces a hybrid dynamic where the corporate entity functions as a vehicle for strategic healthcare investment alongside its core pharmaceutical operations.
What is Hainan Haiyao's relationship with Shenzhen Nanfang Tongzheng Investment?
Shenzhen Nanfang Tongzheng Investment Co., Ltd. is a major shareholder, holding approximately 10% of Hainan Haiyao. This entity also has ties to Chongqing Wanli New Energy, indicating a network of cross-shareholding among Chinese industrial investors. The relationship provides access to broader industrial and financial networks within China.
Where does the underlying investment capital come from?
Investment capital originates from Hainan Haiyao's pharmaceutical operations, including manufacturing, distribution, and sales of generic and specialty drugs, combined with the public equity markets via its Shenzhen Stock Exchange listing. Founder Liu Xicheng's personal wealth, generated from his stake in the company, provides additional, though undisclosed, investment capacity.
Does Hainan Haiyao participate in fund commitments or only direct deals?
The firm engages almost exclusively in direct strategic deals tied to its pharmaceutical operations. There is no public record of Hainan Haiyao making commitments to third-party private equity or venture capital funds. Its investment posture focuses on product licenses, distribution rights, and manufacturing joint ventures rather than LP-style fund investments.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: